Orphan Drugs and Their Impact on Pharmaceutical Development

Trends in Pharmacological Sciences
Misty M AttwoodHelgi B Schiöth

Abstract

High levels of productivity, with an increasing number of approvals for new molecular entities (NMEs) by the FDA during the past decade, have coincided with the emergence of innovative drugs for treatments of rare diseases that have utilized the FDA orphan drug program. Since 2000, NMEs with orphan designation encompass a significant portion of approved drugs and constitute about 80% of the approved drugs that have established novel human genome-encoded products in recent years. Biological approvals are also expanding, with 40% of the approved biological agents having orphan designation. This trend illustrates a pivot within the pharmaceutical industry: from research programs that focus on canonical blockbuster indications and targets, towards the establishment of new treatments for rare and difficult to treat diseases.

References

Jul 30, 2005·Nature Reviews. Drug Discovery·Ernst R BerndtMatthew W Strobeck
Jan 19, 2008·Clinical Pharmacology and Therapeutics·I Kola
Aug 1, 2009·Nature Reviews. Drug Discovery·Eric DavidRodney Zemmel
Jan 1, 2010·Nature Reviews. Drug Discovery·Timothy CotéM Ian Phillips
Feb 20, 2010·Nature Reviews. Drug Discovery·Steven M PaulAaron L Schacht
Jun 2, 2010·Nature Reviews. Drug Discovery·Saurabh Aggarwal
Jun 2, 2011·Nature Reviews. Drug Discovery·Fabio PammolliMassimo Riccaboni
Jun 21, 2011·Orphanet Journal of Rare Diseases·Steven Simoens
Aug 2, 2011·Nature Reviews. Drug Discovery·Mathias Rask-AndersenHelgi B Schiöth
Mar 1, 2012·Drug Discovery Today·Kiran N MeekingsJohn E Arrowsmith
Mar 2, 2012·Nature Reviews. Drug Discovery·Jack W ScannellBrian Warrington
Mar 31, 2012·Nature Reviews. Drug Discovery·Irena Melnikova
Jun 2, 2012·Nature Reviews. Drug Discovery·Roy BerggrenKatarzyna Smietana
Aug 9, 2012·BMJ : British Medical Journal·Donald W Light, Joel R Lexchin
Apr 9, 2013·Drugs·Philip HairKate McKeage
Jun 13, 2013·Clinical Pharmacology and Therapeutics·B Munos
Jul 25, 2013·Orphanet Journal of Rare Diseases·Pierrick RolletMarc Dunoyer
Sep 11, 2013·Annual Review of Pharmacology and Toxicology·Mathias Rask-AndersenHelgi B Schiöth
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·N TomitaB Falissard
May 21, 2016·Nature Reviews. Drug Discovery·Katarzyna SmietanaMartin Møller
Dec 3, 2016·Nature Reviews. Drug Discovery·Rita SantosJohn P Overington
Dec 9, 2016·Nucleic Acid Therapeutics·Annemieke Aartsma-Rus, Arthur M Krieg
Jan 22, 2017·British Journal of Clinical Pharmacology·Elin H DaviesDyfrig A Hughes
Aug 18, 2017·American Journal of Medical Genetics. Part a·Lucas KempfRobert Temple
Oct 28, 2017·Drug Discovery Today·Matthias P HoferStiina Aarum
Nov 11, 2017·Nucleic Acids Research·David S WishartMichael Wilson

❮ Previous
Next ❯

Citations

Aug 28, 2019·Journal of Neuromuscular Diseases·Inès BarthélémyLaurent Tiret
Sep 12, 2019·Internal Medicine Journal·George Laking
Nov 7, 2019·Orphanet Journal of Rare Diseases·Mohua Chakraborty Choudhury, Gayatri Saberwal
Mar 11, 2020·Frontiers in Pharmacology·Miquéias Lopes-Pacheco
Feb 11, 2020·Frontiers in Cell and Developmental Biology·Misty M Attwood, Helgi B Schiöth
Jul 18, 2018·Orphanet Journal of Rare Diseases·Eric T Rush
Sep 3, 2020·Nature Reviews. Drug Discovery·Misty M AttwoodHelgi B Schiöth
Jan 27, 2020·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Rydvikha GovenderStaffan Folestad
Jun 7, 2020·Translational Research : the Journal of Laboratory and Clinical Medicine·Daohong Chen, Eric Yining Qi
May 11, 2021·British Journal of Clinical Pharmacology·Andrey D BondarevHelgi B Schiöth
May 25, 2021·Clinical Pharmacology and Therapeutics·Kyunghun ParkGilbert J Burckart
Jul 17, 2021·Cost Effectiveness and Resource Allocation : C/E·Zoltán KalóAndrás Inotai
Aug 7, 2021·Nature Reviews. Drug Discovery·Misty M AttwoodHelgi B Schiöth
Aug 11, 2021·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Dony PatelJoseph Kim
Nov 20, 2020·ACS Medicinal Chemistry Letters·Todd J Wills, Alan H Lipkus
Aug 12, 2021·British Journal of Pharmacology·Farzin ZobdehJessica Mwinyi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Orphanet Journal of Rare Diseases
Enrique Seoane-VazquezJay Visaria
Drug Discovery Today
Rebekah H Griesenauer, Michael S Kinch
Nature Reviews. Drug Discovery
Timothy CotéM Ian Phillips
American Family Physician
T J McGinnis
© 2022 Meta ULC. All rights reserved